A randomized, placebo-controlled, double-blind, repeat dose, dose escalation trial to investigate the safety, tolerability and pharmacokinetics of supratherapeutic doses of GSK189075 [remogliflozin etabonate] administered for 3 days in healthy volunteers.

Trial Profile

A randomized, placebo-controlled, double-blind, repeat dose, dose escalation trial to investigate the safety, tolerability and pharmacokinetics of supratherapeutic doses of GSK189075 [remogliflozin etabonate] administered for 3 days in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Remogliflozin etabonate (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Aug 2007 Status change
    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top